Internal Medicine Alert – December 15, 2008
December 15, 2008
View Issues
-
Reshuffling the Medication Choices for Type 2 Diabetes
Leaders of the American Diabetes Association (ADA) joined with leaders of the European Association for the Study of Diabetes to reconsider the treatment strategy for patients with Type 2 diabetes. -
Hip Fractures Associated with Low Vitamin D
Women who had low serum 25(OH) vitamin D concentrations were observed to have a higher hip fracture risk independent of other factors. -
Does Ezetimibe Cause Cancer?
The available results from three ezetimibe/simvastatin trials did not provide credible evidence of any adverse effects of ezetimibe on the rate of cancer association with ezetimibe administration at the present time. -
Pharmacology Update: Colesevelam Hydrochloride Tablets (Welcholä): Use in Type 2 Diabetes Mellitus
Colesevelam is a bile-sequestering agent approved in 2000 for the treatment of hypercholesterolemia. It has recently been shown to be effective as add-on therapy for Type 2 diabetics. -
Clinical Briefs By Louis Kuritzky, MD
Topical agents, both as monotherapy and in combination, have shown efficacy in management of acne. Benzoyl peroxide (BPO) is one of the most commonly used agents, but despite excellent efficacy, the side effects of skin dryness, burning, erythema, and peeling are sometimes limiting effects of treatment. -
ECG Review: Having New Chest Pain or Not?
The ECG shown was obtained from a 60-year-old man who was seen in the office. How would you interpret this tracing if you did not have more information? Is there cause for potential concern? -
Pharmacology Watch
5-α reductase inhibitors and hip fracture in men; the effects of drug-reimbursement policy on outcomes; new guidelines for type 2 diabetes; beta-blocker-associated brady-cardia is linked to CVD events; FDA Updates.